Ascendiant Capital Markets Lowers Aclarion (NASDAQ:ACON) Price Target to $1.30

Aclarion (NASDAQ:ACON) had its target price cut by equities researchers at Ascendiant Capital Markets from $1.50 to $1.30 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Aclarion Price Performance

Shares of NASDAQ ACON opened at $0.18 on Wednesday. Aclarion has a one year low of $0.16 and a one year high of $7.40. The firm has a fifty day moving average of $0.18 and a 200 day moving average of $0.24.

Institutional Investors Weigh In On Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC purchased a new position in shares of Aclarion, Inc. (NASDAQ:ACON) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 1.40% of Aclarion as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 7.52% of the company’s stock.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.